RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

Benzinga · 1d ago
RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $198 price target.